Core Insights - The company, TQI, aims to assist investors in navigating the current asset bubble profitably [1] - TQI was established in July 2022 with a mission to simplify and enhance the investing experience for all [2] Company Offerings - TQI publishes premium equity research reports on Seeking Alpha, providing a research library and performance tracker [2] - The company offers highly-concentrated, risk-optimized model portfolios tailored to different stages of the investor lifecycle [2] - TQI provides access to proprietary software tools and group chats to enhance investor engagement and support [2] Additional Resources - TQI shares investing insights through various platforms, including a free newsletter, Twitter, and LinkedIn [2]

远距医疗公司Hims & Hers Health(HIMS.US)夜盘大跌超13%，报54.9美元。消息面上，Hims & Hers Health公布，第二季销售额为5.45亿美元，低于市场预期的5.52亿美元；每股收益为0.17美元，则高于预 期的0.15美元。该公司预计第三季度收入将在5.7亿至5.9亿美元之间，区间中值低于市场预期的5.828亿 美元；重申2025年收入指引为23亿至24亿美元，区间中值与市场预期的23.5亿美元一致。(格隆汇) ...

Core Insights - Hims & Hers Health reported Q2 2025 GAAP revenue of $544.8 million, a 73% increase year-over-year, but fell short of the consensus estimate of $551.7 million by 1.2% [1][5] - The company achieved a diluted GAAP earnings per share of $0.17, reflecting a significant year-over-year increase of 183.3% from $0.06 in Q2 2024 [2][6] - Subscriber count reached 2.44 million, marking a 30.8% increase from 1.86 million in Q2 2024, with a 30% rise in monthly online revenue per average subscriber to $74 [2][7] Financial Performance - Adjusted EBITDA rose to $82.2 million, more than doubling from $39.3 million in Q2 2024, indicating improved operational leverage [2][6] - Free cash flow turned negative at $(69.4) million, a significant decline from positive $47.6 million in Q2 2024, raising concerns about cash efficiency [2][9] - Gross margin decreased from 81% in Q2 2024 to 76% in Q2 2025, attributed to changes in product mix and increased costs [6][14] Business Model and Strategy - Hims & Hers Health operates a subscription-based digital healthcare platform, providing telehealth consultations, prescription treatments, and personalized health products [3][4] - Recent strategic priorities include expanding personalized care offerings, increasing specialty support, and investing in technological infrastructure [4][8] - The company is focusing on recurring subscription revenue, with online revenue growing 75% year-over-year, while wholesale revenue declined by 10% [7] Market Expansion and Future Outlook - The company maintains its full-year 2025 revenue guidance of $2.3 billion to $2.4 billion and adjusted EBITDA of $295 million to $335 million [13] - Upcoming initiatives include expanding international presence and launching new specialties such as low testosterone and menopause support [13][14] - The partnership with Novo Nordisk for weight loss treatments is expected to enhance customer options and brand validation [11][12]

分组1 - Hims & Hers Health, Inc. reported quarterly earnings of $0.17 per share, missing the Zacks Consensus Estimate of $0.18 per share, but showing an increase from $0.06 per share a year ago, resulting in an earnings surprise of -5.56% [1] - The company posted revenues of $544.83 million for the quarter ended June 2025, missing the Zacks Consensus Estimate by 1.51%, compared to year-ago revenues of $315.65 million [2] - Hims & Hers Health shares have increased approximately 158.7% since the beginning of the year, significantly outperforming the S&P 500's gain of 6.1% [3] 分组2 - The current consensus EPS estimate for the coming quarter is $0.19 on revenues of $583.31 million, and for the current fiscal year, it is $0.75 on revenues of $2.35 billion [7] - The Medical Info Systems industry, to which Hims & Hers Health belongs, is currently ranked in the top 26% of over 250 Zacks industries, indicating a favorable outlook for the sector [8]

Financial Data and Key Metrics Changes - Revenue grew 73% year over year to $545 million, with an adjusted EBITDA margin above 15% [28][39] - Subscribers increased by 73,000 quarter over quarter to over 2.4 million, reflecting a year-over-year growth rate of 31% [28] - Monthly average revenue per subscriber declined quarter over quarter to $74 from $84, primarily due to offboarding GLP-1 subscribers [30][39] Business Line Data and Key Metrics Changes - Strong performance in dermatology, oral weight loss, and daily sexual health offerings, all sustaining year-over-year subscriber growth rates above 55% [28][29] - Continued success in the weight loss specialty, despite headwinds from offboarding GLP-1 subscribers [29][60] - Daily sexual health offerings are expected to improve retention and customer lifetime value [29] Market Data and Key Metrics Changes - The company is expanding its presence in the UK through the acquisition of Zava, with plans to enter Canada in 2026 focusing on holistic weight loss programs [24][25] - Anticipated launch of generic semaglutide in Canada, expected to significantly reduce consumer price points and improve access [80] Company Strategy and Development Direction - The company aims to democratize access to precision medicine and expand into new specialties, including hormonal health [13][14] - Plans to integrate lab testing capabilities to enhance service offerings and support the hormonal health launch [16][17] - Focus on building a technology-first healthcare platform, leveraging AI for personalized care and operational efficiency [20][21] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the momentum of the business and the demand for personalized healthcare solutions [5][26] - The company anticipates continued growth in subscriber retention and engagement through personalized treatment plans [30][43] - Management acknowledged potential headwinds from the transition of the sexual health specialty but expects long-term benefits from daily offerings [29][60] Other Important Information - The company completed a convertible debt offering, strengthening its balance sheet with over $1.1 billion in cash and short-term investments [34] - Free cash flow for the second quarter was negative $69 million, but positive cash flow generation is expected in the second half of the year [35] Q&A Session Summary Question: Why was now the right time to expand internationally and what made Zava the right company to acquire? - Management believes it is a powerful opportunity to lead in personalized, high-touch, affordable precision medicine globally, with Zava's scalable platform being a key asset [45][47] Question: How does the launch of at-home lab testing improve the business? - Lab testing is seen as foundational for all categories, enabling a transition to preventative health and potentially leading to a membership model similar to Amazon or Costco [50][51] Question: Update on the HERS business performance and growth drivers? - The HERS business continues to grow robustly, driven by dermatology, weight loss, and upcoming hormonal support offerings [66] Question: How is the company approaching AI investments and expected returns? - The company aims for quick, tangible improvements through AI, enhancing efficiency and engagement across the platform [68] Question: Expectations for GLP-1 revenue and future growth? - Management expects continued growth in the weight loss specialty despite recent declines, with a focus on personalized offerings [72][73]

Financial Data and Key Metrics Changes - Revenue grew 73% year over year to $545 million, with an adjusted EBITDA margin above 15% [28][30] - Subscribers increased by 73,000 quarter over quarter to over 2.4 million, reflecting a year-over-year growth rate of 31% [28][30] - Monthly average revenue per subscriber declined quarter over quarter to $74 from $84, primarily due to offboarding of GLP-1 subscribers [30][31] Business Line Data and Key Metrics Changes - Strong performance in dermatology, oral weight loss, and daily sexual health offerings, all sustaining year-over-year subscriber growth rates above 55% in Q2 [28][29] - Continued subscriber adoption of personalized offerings and success in the weight loss specialty drove year-over-year growth in monthly average online revenue per subscriber [30][31] - Headwinds from offboarding GLP-1 subscribers and a decline in the on-demand sexual health subscriber base were noted [29][30] Market Data and Key Metrics Changes - The company is expanding its presence in the UK through the acquisition of Zava, with plans to enter Canada in 2026 focusing on holistic weight loss programs [24][25] - The Canadian market is expected to see a significant opportunity with the anticipated launch of generic semaglutide, potentially reducing consumer price points to $75-$100 [84] Company Strategy and Development Direction - The company aims to democratize access to precision medicine and expand into new specialties, targeting $6.5 billion in revenue and $1.3 billion in adjusted EBITDA by 2030 [13] - Upcoming launches in hormonal health and lab testing are seen as significant steps forward, with a focus on personalized solutions for hormonal changes [14][15] - The integration of lab testing capabilities is expected to transform care delivery and support the company's long-term vision of preventive health [15][20] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to navigate challenges and emphasized the importance of consumer-centric healthcare [26][44] - The company anticipates continued robust growth and has established a foundation of talent and capabilities to unlock value for millions globally [44] - Management acknowledged headwinds from the rotation of the sexual health specialty but expects stronger retention from daily offerings in the future [29][44] Other Important Information - The company completed a convertible debt offering, ending Q2 with over $1.1 billion in cash and short-term investments [34][35] - Free cash flow for Q2 was negative $69 million, but positive cash flow generation is expected in the second half of the year [35] Q&A Session Summary Question: Why was now the right time to expand internationally and what made Zava the right company to acquire? - Management highlighted the opportunity to lead in personalized, high-touch, affordable precision medicine globally, with Zava's scalable platform being a key factor [46][47][49] Question: How does the launch of at-home lab testing improve the business? - Management emphasized the importance of making testing affordable and accessible, which could lead to a membership model similar to Amazon or Costco [51][54][56] Question: Can you provide an update on the HERS business performance? - The HERS business continues to grow robustly, driven by dermatology, weight loss, and mental health offerings, with hormonal support for menopause expected to launch soon [68] Question: How is the company approaching AI investments? - The company aims to build an AI strategy that delivers tangible improvements quickly, enhancing efficiency and engagement across the platform [70][72] Question: What are the expectations for the GLP-1 segment moving forward? - Management expects continued growth in the weight loss specialty despite recent headwinds, with a focus on personalized offerings [75][76] Question: How should investors think about inventory levels going forward? - The increase in inventory was strategic to ensure a durable supply for new specialties, with expectations that this will not be a recurring trend [96][98]

and hims and hers earnings are out as well. Our Brandon Gomez has those numbers. Brandon, hey John.Yeah, you can see shares moving down just about 10%. A little confusion here for investors. I mean, you have a beat um on EPS.Uh revenues did come in a bit light for the quarter reaffirmed guidance for the fiscal year as well as Q3. What did come in very light was Q3 adjusted Ebida. I just got off the phone with the company's CFO.He talked to me about what some of the cause of that is. He said, "Our focus is o ...

hims & hers SUPPLEMENTAL PRESENTATION Investor Presentation August 2025 > INTRODUCTION Safe Harbor Statement This presentation has been prepared by Hims & Hers Health, Inc. ("we," "us," "us," "Hims & Hers," or the "Company"). This presentation includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and performance to be materially different from those expressed or implied by these forward-looking statements. These risks and Section 21E of the Securitie ...

Core Insights - Hims & Hers Health reported a 73% increase in revenue for the second quarter, reaching $544.8 million compared to $315.6 million in the same period last year [1] - The company experienced a net income of $42.5 million, or 17 cents per share, up from $13.3 million, or 6 cents per share, year-over-year [1] - Despite strong year-over-year growth, the company's second-quarter results fell short of Wall Street's revenue expectations, leading to a 9% decline in shares during extended trading [1] Revenue Expectations - For the third quarter, Hims & Hers anticipates revenue between $570 million to $590 million, slightly below analysts' expectations of $583 million [2] - The adjusted EBITDA for the upcoming quarter is projected to be between $60 million to $70 million, while analysts had expected $77.1 million [2] Earnings Comparison - The adjusted earnings per share for the second quarter were reported at 17 cents, compared to an expectation of 15 cents [3] - Revenue for the second quarter was reported at $544.8 million, which was slightly below the expected $552 million [3]

Financial Performance - Revenue for Q2 2025 reached $544.8 million, a 73% increase from $315.6 million in Q2 2024[20] - Gross profit for Q2 2025 was $416.2 million, compared to $256.6 million in Q2 2024, reflecting a 62% increase[20] - Net income for the first half of 2025 was $92.0 million, significantly up from $24.4 million in the same period of 2024[20] - Total revenue for the six months ended June 30, 2025, reached $1.13 billion, compared to $593.82 million for the same period in 2024, reflecting a 90% year-over-year growth[52] - Segment net income for the three months ended June 30, 2025, was $42.505 million, up from $13.297 million in the same period of 2024, indicating a significant growth in profitability[152] - Net income for Q2 2025 was $42.5 million, a significant increase of 220% from $13.3 million in Q2 2024[203] Assets and Liabilities - Total current assets increased to $1.36 billion as of June 30, 2025, compared to $395.8 million at the end of 2024[18] - Total assets reached $1.88 billion as of June 30, 2025, up from $707.5 million at the end of 2024[18] - Total liabilities increased to $1.31 billion as of June 30, 2025, compared to $230.8 million at the end of 2024[18] - Stockholders' equity rose to $562.7 million as of June 30, 2025, up from $476.7 million at the end of 2024[18] Cash Flow and Investments - Cash and cash equivalents increased to $1.12 billion as of June 30, 2025, compared to $220.6 million at the end of 2024[18] - Net cash provided by operating activities increased to $89,973 for the six months ended June 30, 2025, up from $79,432 in 2024, reflecting a growth of 13.5%[29] - The company incurred $101,392 in purchases of property, equipment, and intangible assets during the six months ended June 30, 2025, compared to $13,793 in 2024, reflecting a significant increase of 634%[29] - The company recognized cash paid for taxes of $23,047 for the six months ended June 30, 2025, compared to $3,468 in 2024, representing a substantial increase of 563%[29] - The company’s total cash flow from investing activities was negative at $(53,884) for the six months ended June 30, 2025, compared to a positive cash flow of $8,572 in 2024, indicating a significant shift in investment cash flow[29] Revenue Streams - Online Revenue for the three months ended June 30, 2025, was $536.88 million, a 75% increase from $306.84 million in the same period of 2024[52] - The Company's GLP-1 offerings generated approximately $190 million and $420 million in Online Revenue for the three and six months ended June 30, 2025, respectively[171] - Wholesale Revenue for the three months ended June 30, 2025, was $8.0 million, a decrease of $0.9 million, or 10%, compared to $8.8 million for the same period in 2024[173] Expenses - Operating expenses for Q2 2025 were $389.5 million, up from $245.6 million in Q2 2024, representing a 58% increase[20] - Marketing expenses for Q2 2025 were $217.9 million, a 50% increase from $144.9 million in Q2 2024[203] - Technology and development expenses for Q2 2025 were $37.8 million, a 103% increase from $18.7 million in Q2 2024[203] - General and administrative expenses for Q2 2025 were $67.3 million, a 66% increase from $40.6 million in Q2 2024[203] Acquisitions - The Company acquired C S Bio Co. for up to $39.1 million to enhance supply chain capabilities, with an upfront payment of approximately $32.7 million[63] - The acquisition of Sigmund NJ, LLC (Trybe Labs) was completed for $5.1 million, adding lab testing capabilities to the platform[66] - The Company acquired Zava Global GmbH for up to approximately EUR 225.0 million ($265.7 million), aiming to expand its footprint in the UK and enter European markets[158] Stock and Equity - The 2024 Share Repurchase Program allows for the repurchase of up to $100.0 million of Class A common stock, with $65.0 million remaining available as of June 30, 2025[119] - For the six months ended June 30, 2025, the company released 3,783,712 gross shares of Class A common stock upon vesting of RSUs, with 1,420,506 shares withheld for employee taxes[120] - As of June 30, 2025, there were 65,403,042 shares of Class A common stock reserved and 22,285,450 shares available for grant under the 2020 Equity Incentive Plan[122] Future Outlook - The Company anticipates that personalized offerings will increasingly drive Online Revenue growth in the future[171] - The company expects to continue investing in fulfillment, distribution, and operating capabilities, including its recently acquired facilities, over the next 12 months[179] - The company anticipates that the resolution of the semaglutide shortage will impact Subscriber retention and revenue in the near term[178]